Perimeter Medical Imaging AI (PINK) Investor Update summary

Technology and product overview

• Two main products: S-Series (FDA-cleared, commercially available) and B-Series (in clinical trial, AI-enabled).

• OCT imaging provides high-resolution, real-time margin assessment during oncological surgery.

• AI algorithms highlight suspicious areas, streamlining surgeon workflow and improving accuracy.

• Proprietary image library and strong IP protection create a significant competitive moat.

• Technology applicable to other markets, including biopsy and pathology, with minimal additional R&D.

Clinical and economic impact

• S-Series use reduced breast cancer reoperation rates from 20% nationally to 5.6% in a Texas study.

• IDC subgroup saw zero reoperations with OCT, compared to 18% national average.

• Potential to save nearly $500 million annually in U.S. breast cancer re-excisions alone.

• Improved first-surgery success rates linked to higher five-year survival rates.

• Ongoing studies and papers are expanding evidence base and clinical validation.

Commercial strategy and growth

• Focused initial commercialization in select U.S. states, targeting early adopters.

• Expansion planned as S-Series reputation grows and B-Series nears FDA approval (expected late 2025).

• Sales pipeline is robust, with word-of-mouth driving surgeon interest.

• Main barrier to expansion is scaling the sales organization to meet demand.

• Licensing opportunities and strategic partnerships are being explored for broader market reach.